phase iii data support frontline osimertinib in egfr-mutant lung cancers
Published 4 years ago • 349 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
1:21
fda approval of frontline osimertinib in frontline egfr-mutant nsclc
-
1:24
egfr tkis excite treatment landscape of egfr-mutant lung cancers
-
3:09
case 2: osimertinib in egfr-mutated lung cancer
-
1:02
osimertinib for treatment of egfr lung cancer
-
5:18
frontline therapy for egfr plus nsclc: osimertinib’s impact
-
2:04
dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
-
0:50
treating patients with egfr-mutant lung cancer with targeted therapies
-
5:13
case 2: frontline therapy in egfr-mutated lung cancer
-
5:55
a case of egfr-mutant non–small cell lung cancer
-
4:09
frontline afatinib in egfr-mutant nsclc
-
6:51
osimertinib as frontline therapy in egfr-positive nsclc
-
2:27
dr. west discusses results of the phase iii flaura study in nsclc
-
4:04
treating with osimertinib in egfr-mutated nsclc
-
2:27
significance of the phase iii flaura study in egfr nsclc
-
5:24
case 4: egfr mutation analysis post-osimertinib
-
1:13
identification of egfr mutations impact overall prognosis in lung cancers
-
1:36
comment: front-line osimertinib significantly lengthens overall survival in egfr-mutation positi...
-
0:48
investigating osimertinib for brain activity in egfr-mutated lung cancer
-
3:27
egfr-mutant nsclc: selecting patients for osimertinib